Evenity vs Forteo
A side-by-side look at two bone health medications advertised on TV. Informational only — not medical advice.
| US Evenity | US Forteo | |
|---|---|---|
| Generic name | romosozumab | teriparatide |
| Drug class | Sclerostin Inhibitor (Biologic) | Parathyroid Hormone Analog |
| Treats | Osteoporosis (high fracture risk) | Osteoporosis |
| Category | Bone Health | Bone Health |
| Manufacturer | Amgen/UCB | Eli Lilly |
| Year approved | 2019 | 2002 |
| FDA warning | Black box warning | Moderate warnings |
| Est. TV ad spend | $70M | — |
| Common side effects | Heart attack or stroke risk, Joint pain, Headache, Low blood calcium | Dizziness, Leg cramps, Nausea, Joint pain |
Frequently asked questions
Is Evenity or Forteo better?
Neither is universally "better." Evenity (romosozumab) and Forteo (teriparatide) are both used for bone health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Evenity and Forteo?
Evenity is a Sclerostin Inhibitor (Biologic) made by Amgen/UCB, while Forteo is a Parathyroid Hormone Analog made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Evenity has the larger estimated TV advertising budget of the two.